CA2364258C - 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis - Google Patents

3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis Download PDF

Info

Publication number
CA2364258C
CA2364258C CA002364258A CA2364258A CA2364258C CA 2364258 C CA2364258 C CA 2364258C CA 002364258 A CA002364258 A CA 002364258A CA 2364258 A CA2364258 A CA 2364258A CA 2364258 C CA2364258 C CA 2364258C
Authority
CA
Canada
Prior art keywords
multiple sclerosis
benzamide
difluoromethoxy
cyclopropylmethoxy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002364258A
Other languages
English (en)
French (fr)
Other versions
CA2364258A1 (en
Inventor
Hans-Peter Kley
Karl Sanders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CA2364258A1 publication Critical patent/CA2364258A1/en
Application granted granted Critical
Publication of CA2364258C publication Critical patent/CA2364258C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002364258A 1999-03-10 2000-03-01 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis Expired - Fee Related CA2364258C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99104793 1999-03-10
EP99104793.7 1999-03-10
PCT/EP2000/001703 WO2000053182A2 (en) 1999-03-10 2000-03-01 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
CA2364258A1 CA2364258A1 (en) 2000-09-14
CA2364258C true CA2364258C (en) 2008-12-30

Family

ID=8237737

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364258A Expired - Fee Related CA2364258C (en) 1999-03-10 2000-03-01 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis

Country Status (12)

Country Link
US (1) US6531493B1 (cg-RX-API-DMAC10.html)
EP (1) EP1161239B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002538207A (cg-RX-API-DMAC10.html)
AT (1) ATE279924T1 (cg-RX-API-DMAC10.html)
AU (1) AU3284000A (cg-RX-API-DMAC10.html)
CA (1) CA2364258C (cg-RX-API-DMAC10.html)
DE (1) DE60015098T2 (cg-RX-API-DMAC10.html)
DK (1) DK1161239T3 (cg-RX-API-DMAC10.html)
ES (1) ES2231162T3 (cg-RX-API-DMAC10.html)
PT (1) PT1161239E (cg-RX-API-DMAC10.html)
SI (1) SI1161239T1 (cg-RX-API-DMAC10.html)
WO (1) WO2000053182A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060084684A1 (en) 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
DE69532238T2 (de) * 1994-04-21 2004-10-21 Schering Ag Pde iv-inhibitoren zur behandlung der multiplen sklerose

Also Published As

Publication number Publication date
EP1161239B1 (en) 2004-10-20
DK1161239T3 (da) 2005-02-14
SI1161239T1 (en) 2005-06-30
PT1161239E (pt) 2005-02-28
DE60015098T2 (de) 2006-02-02
JP2002538207A (ja) 2002-11-12
CA2364258A1 (en) 2000-09-14
EP1161239A2 (en) 2001-12-12
WO2000053182A2 (en) 2000-09-14
US6531493B1 (en) 2003-03-11
ATE279924T1 (de) 2004-11-15
WO2000053182A3 (en) 2001-04-12
AU3284000A (en) 2000-09-28
ES2231162T3 (es) 2005-05-16
DE60015098D1 (de) 2004-11-25

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
Smith Cocaine-alcohol abuse: epidemiological, diagnostic and treatment considerations
AU2025210905A1 (en) Method of treatment with tradipitant
WO1991013627A1 (en) Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
JPH06102622B2 (ja) 肥満の治療
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
EP1161239B1 (en) 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6555576B1 (en) Method for treating exercise induced asthma
Lewis et al. Dose effects of chlorpromazine on human sleep
JP2002511087A (ja) ブプレノルフィンを用いる慢性疲労症候群および線維筋痛症の治療方法
Saphier et al. α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat
US4735968A (en) Method of treating tinnitus with AOAA
US6897229B2 (en) Synergistic combination comprising roflumilast and a PDE-3 inhibitor
RU2316341C2 (ru) Применение атазанавира в терапии вич-инфекции
Schneider et al. Impotence in patients treated with clofibrate
US4355044A (en) D-Phenylalanine treatment
CA2112195A1 (en) Preventive and therapeutic agent for arteriosclerosis
US4431670A (en) D-Phenylalanine treatment
EP0764025A1 (en) Method and medicine for alleviating jet lag
Jenkins et al. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis
US20060166994A1 (en) Method for treating renal failure
JP2593910B2 (ja) パニック障害の予防又は抑制剤
KR960014873B1 (ko) 제피론을 함유하는 공황(恐慌)장애 경감용 약학 조성물
Langrehr, D., Agoston, S., Erdmann, W. & Newton Pharmacodynamics and reversal of benzodiazepine-ketamine ataranalgesia

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170301